^
    almost3years
    Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1b, N=24, Completed, Celgene | Active, not recruiting --> Completed
    Trial completion
    |
    GLI1 (GLI Family Zinc Finger 1)
    |
    CC-95775
    3years
    Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1b, N=24, Active, not recruiting, Celgene | Trial primary completion date: Jul 2021 --> Oct 2021
    Clinical • Trial primary completion date
    |
    GLI1 (GLI Family Zinc Finger 1)
    |
    CC-95775
    over3years
    Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1b, N=24, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting | N=40 --> 24
    Clinical • Enrollment closed • Enrollment change
    |
    GLI1 (GLI Family Zinc Finger 1)
    |
    CC-95775
    almost4years
    Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1b, N=40, Recruiting, Celgene | Trial completion date: Jun 2023 --> Jul 2021 | Trial primary completion date: Jun 2023 --> Jul 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    GLI1 (GLI Family Zinc Finger 1)
    |
    CC-95775